Gleevec

US generics business that accounts for nearly half of Sun Pharma sales grew at a moderate pace of 4 percent USD 507 million in the third quarter.

Q3 results: Five trends to watch out from Indian drugmakers

Analysts predict Q3 to be a tough quarter with revenue growth moderating to 11.7 percent in October-December period compared to 18.4 percent compounded annual growth rate (CAGR) over last 10 years

Sun Pharma Q2 profit seen up 52%, US sales may drive revenue

Healthcare major Sun Pharmaceutical Industries' second quarter profit is seen rising 52.3 percent year-on-year to Rs 1,685 crore on strong operational performance.

Sun Pharma Q1 net seen at Rs 1894 cr, US sales likely at $598 mn

According to a CNBC-TV18 poll, the drug major is likely to see revenue growth of 20.2 percent at Rs 7876.6 crore in Q1 against Rs 6552.2 crore in year-ago period.

Sun Pharma gains; launches Imatinib Mesylate in US market

The company's subsidiary has received final approval for Imatinib Mesylate from Food and Drug Administration (FDA) in December 2015.

Sun hopes cut-price generic Gleevec will win third of US market

Gleevec, or imatinib mesylate, costs up to about USD 90,000 annually in the United States, implying Sun's price could be roughly USD 60,000. Gleevec posted USD 4.7 billion in global revenue in 2015, and Swiss-based Novartis has said the US patent expiry puts around USD 2.5 billion in annual sales at risk.

Sun Pharma rises 3%, CLSA retains buy on 72% FY17 EPS growth

CLSA says Sun's FY17 EPS will be driven by Gleevec generic launch in the United States & synergy benefits with Ranbaxy that merged with effect from April 2015.

Sun Pharma sinks 7% on warning letter but analysts bullish

However, most analysts are still bullish on the stock and are keenly waiting to for more details in the warning letter. Few analysts have lowered target price with a cautious outlook. Phillip Capital remains positive and advises to buy on dips stating that the issue may have more sentimental impact.

Sun Pharma up 6% on USFDA nod for anti-cancer drug Gleevec

"The subsidiary today has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Gleevec, imatinib mesylate tablets 100mg and 400mg," says the country's largest drug maker in its filing.